Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Ross

Showing results (21-30 of 130) with videos related to

Pageof 13
Sort By:
The Medical Journal of Australia|December 9, 2020
Sudden onset vision loss: an atypical presentation of giant cell arteritis and myeloproliferative neoplasmKhizar Rana, Carmen Oakley, David M Ross, et al.
Blood|January 6, 2025
The Evolution of Treatment-Free RemissionTimothy P Hughes, Agnes Sm Yong, David M Ross
Expert Opinion on Pharmacotherapy|May 12, 2015
Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemiaAnya K Hotinski, Ian D Lewis, David M Ross
Pathology|March 19, 2022
Identification of two novel transcobalamin 2 variants associated with developmental delay and megaloblastic anaemia in infancyJonathan Lim, Rachel Hall, Scott Grist, et al.
Blood|August 22, 2024
Identifying disease-modifying potential in myelofibrosis clinical trialsDavid M Ross, Steven W Lane, Claire N Harrison
Journal of the Air & Waste Management Association (1995)|October 31, 2017
Human Visual Sensitivity to Plumes with a GaussianDavid M Ross, William C Malm, Hariharan K Iyer
Journal of Alzheimer'S Disease : JAD|June 9, 2020
Meta-Analysis of Memory-Focused Training and Multidomain Interventions in Mild Cognitive ImpairmentDale S Sherman, Kelly A Durbin, David M Ross
Leukemia & Lymphoma|August 14, 2023
Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national surveyAlexandra Murton, Cecily Forsyth, David M Ross, et al.
Haematologica|January 21, 2021
Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implicationsDavid M Ross, Jeffrey J Babon, Denis Tvorogov, et al.
Clinical Chemistry|July 22, 2008
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual diseaseDavid M Ross, Dale B Watkins, Timothy P Hughes, et al.
Pageof 13

Showing results (21-30 of 130) with videos related to

Sort By:
Pageof 13
The Medical Journal of Australia|December 9, 2020
Sudden onset vision loss: an atypical presentation of giant cell arteritis and myeloproliferative neoplasmKhizar Rana, Carmen Oakley, David M Ross, et al.
Blood|January 6, 2025
The Evolution of Treatment-Free RemissionTimothy P Hughes, Agnes Sm Yong, David M Ross
Expert Opinion on Pharmacotherapy|May 12, 2015
Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemiaAnya K Hotinski, Ian D Lewis, David M Ross
Pathology|March 19, 2022
Identification of two novel transcobalamin 2 variants associated with developmental delay and megaloblastic anaemia in infancyJonathan Lim, Rachel Hall, Scott Grist, et al.
Blood|August 22, 2024
Identifying disease-modifying potential in myelofibrosis clinical trialsDavid M Ross, Steven W Lane, Claire N Harrison
Journal of the Air & Waste Management Association (1995)|October 31, 2017
Human Visual Sensitivity to Plumes with a GaussianDavid M Ross, William C Malm, Hariharan K Iyer
Journal of Alzheimer'S Disease : JAD|June 9, 2020
Meta-Analysis of Memory-Focused Training and Multidomain Interventions in Mild Cognitive ImpairmentDale S Sherman, Kelly A Durbin, David M Ross
Leukemia & Lymphoma|August 14, 2023
Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national surveyAlexandra Murton, Cecily Forsyth, David M Ross, et al.
Haematologica|January 21, 2021
Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implicationsDavid M Ross, Jeffrey J Babon, Denis Tvorogov, et al.
Clinical Chemistry|July 22, 2008
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual diseaseDavid M Ross, Dale B Watkins, Timothy P Hughes, et al.
Pageof 13